financetom
Business
financetom
/
Business
/
Union Pacific, Norfolk Southern explore cross-continental railroad merger, source says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Union Pacific, Norfolk Southern explore cross-continental railroad merger, source says
Jul 18, 2025 1:43 PM

NEW YORK (Reuters) -Union Pacific, the largest U.S. freight railroad operator, is exploring a possible acquisition of Norfolk Southern to create a $200 billion coast-to-coast rail network, a person familiar with the matter said.

Talks are in early stages, the person said, with no guarantee talks will progress or that any deal would pass what would be expected to be a lengthy, detailed regulatory review. The two companies declined to comment.

Any deal to unite two of the six largest freight rail operators in North America is likely to draw intense regulatory scrutiny. Major shippers in the steel, chemical and grain industries are expected to lobby against any further concentration in an industry that has consolidated from over 100 Class I railroads in the 1950s to just six today.

Union Pacific shares fell 2.7% in Friday afternoon trading, while Norfolk Southern rose 1.52%.

A combination would mark a shift in the U.S. freight rail landscape, creating a single-line network stretching from coast to coast, changing the current divide between western and eastern regional operators.

Norfolk is recovering from a tumultuous past couple of years that included the firing of its previous CEO amid ethics investigations, a boardroom battle with activist Ancora, and a train derailment that cost the company about $1.4 billion.

CONCENTRATION

A merger between Union Pacific and Norfolk Southern would create the first modern West-to-East single-line freight railroad in the U.S.

Earlier this year, Union Pacific CEO Jim Vena said a transcontinental merger would be good for customers, eliminating the need for interchanges between carriers in Chicago - a longstanding bottleneck - and reducing costly delays for shippers.

But critics warn that such consolidation could reduce competition, a possible concern for regulators. With fewer major players in the market, shippers may face higher costs and diminished service options.

"We suspect certain shipper groups could get vocal on the perceived lost competition a merger would bring," Barclays analyst Brandon R. Oglenski said.

Discussions between the two operators, first disclosed by Semafor, spurred speculation that competitors would also consider concentration.

"History teaches that mergers and acquisitions within the railroad industry will inspire and motivate additional M&A," said Mike Steenhoek, executive director of the Soy Transportation Coalition.

That happened earlier this decade when Canadian Pacific offered to acquire Kansas City Southern, which prompted CP's main competitor - Canadian National - to submit their own offer to acquire Kansas City Southern.

Ultimately the Canadian National offer was not allowed to proceed, and Canadian Pacific did acquire Kansas City Southern in 2023 - creating the first railroad to link Canada, the U.S. and Mexico.  

In 2024, Union Pacific led the industry with $24.3 billion in revenue, followed by BNSF (privately held, owned by Berkshire Hathaway), CSX, Canadian National, Norfolk and Canadian Pacific Kansas City.

"The energy and momentum toward the remaining two U.S. based Class I railroads - BNSF and CSX - pursuing a merger would be considerable," Steenhoek said.

A regulatory decision could take 16 to 22 months, with merging carriers required to notify the Surface Transportation Board three to six months before filing an application, followed by a year-long evidentiary review and a final ruling within 90 days, Oglenski said.

A potential Union Pacific acquisition of Norfolk Southern could have material synergy, he said.

"Any deal would face serious review from regulators," said Emily Nasseff Mitsch, equity analyst at CFRA.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved